TP53 and neoplasm: YY2 downregulation in various tumors, including colorectal, prostate, ovarian, and liver cancers, is closely associated with poor survival and prognosis.[53, 54, 55] While previous studies have revealed that YY2 can trigger ferroptosis, ultraviolet damage response, and p53‐mediated cell cycle arrest,[29, 31, 56] studies regarding its physiological and pathological functions are still very limited, and the mechanisms underlying its tumor suppressive effect have not been completely elucidated.